In a report released on March 14, Akash Tewari from Jefferies maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a ...

BofA raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $213 from $182 and keeps a Buy rating on the shares. The Phase 3 ...

Atria Investments Inc lifted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 19.5% during the fourth ...

Dublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus on neuroscience and oncology. JAZZ is a Zacks Rank #2 (Buy) stock, with a Value Style Score of A ...

Jazz Pharmaceuticals, a Zacks Rank #1 (Strong Buy), is a specialty biopharmaceutical company that identifies, develops, and commercializes pharmaceutical products in the United States, Europe ...

Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Dublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus on neuroscience and oncology. JAZZ is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.

The headbands were out on Wednesday in Memphis. All but one member of the Utah Jazz sported white NBA headbands for its game ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex. Nasdaq-listed GW is in line for $220 ...